Boehringer Ingelheim’s interchangeable biosimilar to Humira now available at a discount
RIDGEFIELD, Conn. – Adalimumab-adbm is approved to treat multiple chronic inflammatory diseases and will be priced at an 81% discount to Humira. It is also available under the brand name Cyltezo, which launched in July 2023 and is priced at a 5% discount to Humira.